Drug Profile
Research programme: small molecule immunomodulators - iTeos Therapeutics/Pfizer
Latest Information Update: 28 Jan 2019
Price :
$50
*
At a glance
- Originator iTeos Therapeutics
- Developer iTeos Therapeutics; Pfizer
- Class Small molecules
- Mechanism of Action Indoleamine-pyrrole 2,3-dioxygenase inhibitors; Tryptophan oxygenase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 28 Jan 2019 No recent reports of development identified for research development in Cancer in Belgium
- 28 Jan 2019 No recent reports of development identified for research development in Cancer in USA
- 07 Dec 2016 iTeos Therapeutics in-licenses medicinal nanotechnology CriPec® platform technology from Cristal Therapeutics